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H I G H L I G H T S    
• CBT for internalizing disorders treated in routine clinical care was meta-analyzed.  • Attrition during CBT was low (5–15%).  • CBT was effective in reducing symptoms and increasing remission.  • Outcome was significantly improved from post- to follow-up assessment.  • The outcomes of effectiveness studies were on a par with that of efficacy studies.  
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A B S T R A C T   
Cognitive behavioral therapy (CBT) has received considerable empirical support for internalizing disorders in-
cluding anxiety, depression, obsessive-compulsive disorder, and post-traumatic stress disorder in children and 
adolescents. However, there is less knowledge regarding how CBT performs when delivered in routine clinical 
care. A systematic review and meta-analysis was conducted of CBT for internalizing disorders in children and 
adolescents in routine clinical care. Ovid MEDLINE, Embase OVID, and PsycINFO were systematically searched 
for articles published until October 2019. The effectiveness of CBT, methodological quality, and moderators of 
treatment outcome were examined. The effects of CBT in routine clinical care were benchmarked by comparing 
with efficacy studies for the same disorders. Fifty-eight studies were included, comprising 4618 participants. 
Large effect sizes for outcome were detected at post-treatment (g = 1.28–2.54), and follow-up (g = 1.72–3.36). 
Remission rates across diagnoses ranged from 50.7% - 77.4% post-treatment, to 53.5% -83.3% at follow-up. 
Attrition rate across the disorders was 12.2%. Quality of the included studies was fair, and heterogeneity was 
high. Similarities between the effectiveness and efficacy studies were greater than the differences in outcome. 
CBT delivered in routine clinical care is efficacious in reducing internalizing disorders and symptoms. The 
outcomes are comparable with results obtained in efficacy studies. 
PROSPERO registration: ID CRD42019128709.   
1. Introduction 
Internalizing disorders such as anxiety disorders, obsessive com-
pulsive disorder (OCD), post-traumatic stress disorder (PTSD), and de-
pressive disorders, represent as a group the most common mental 
health disorders among children and adolescents (Costello, Egger, & 
Angold, 2005; Merikangas et al., 2010). These disorders represent 
partly overlapping variations of emotional distress and symptom 
presentations in response to life stressors and difficulties (Nigatu et al., 
2016). They are associated with numerous negative mental health 
outcomes, and can lead to psychological, cognitive, social and occu-
pational impairments (Asselmann, Wittchen, Lieb, & Beesdo-Baum, 
2018; de Lijster et al., 2018; Kertz, Petersen, & Stevens, 2019;  
Piacentini, Bergman, Keller, & McCracken, 2003; Trickett, Noll, & 
Putnam, 2011; Wu et al., 2016). 
Effective and empirically supported treatments for these disorders 
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in children and adolescents exist, with cognitive behavioral therapy 
(CBT) approaches having empirical support for anxiety disorders, OCD, 
PTSD and depressive disorders (Dorsey et al., 2017; Freeman et al., 
2018; Higa-McMillan, Francis, Rith-Najarian, & Chorpita, 2016;  
Weersing, Jeffreys, Do, Schwartz, & Bolano, 2017). However, the evi-
dence for the efficacy of empirically supported treatments such as CBT 
rests mainly on randomized controlled trials conducted in specialized 
university research settings, i.e. efficacy trials. An important question is 
how well CBT holds up when transported and delivered in routine 
clinical practice (Lee, Horvath, & Hunsley, 2013; Weisz, Ugueto, 
Cheron, & Herren, 2013). 
The question of transportability of empirically supported treatment 
into routine clinical practice is partly grounded in a concern that the 
methodological rigor of efficacy trials to maximize experimental control 
may sometimes decrease the external validity and limit the general-
izability of the findings (La Greca, Silverman, & Lochman, 2009). 
Concerns about the generalizability of results from RCTs arises from the 
assumptions that clients, therapists and treatment contexts may all 
differ in important ways between research clinics and community 
clinics (Hunsley, 2007; Lee et al., 2013; Weisz, Ng, Rutt, Lau, & 
Masland, 2013; Weisz, Ugueto, et al., 2013). Participants in efficacy 
trials are usually subjects to more rigorous inclusion and exclusion 
criteria, and may therefore be more homogenous compared with clients 
in community clinics (Hunsley, 2007; Weisz, Ng, et al., 2013). For ex-
ample, many inclusion and exclusion criteria may be applied in se-
lecting participants for an efficacy study to minimize the influence of 
external factors on the treatment. Inclusion criteria are used to ensure 
that all participants have the condition for which the treatment has 
been designed (i.e., carefully diagnosed disorders), and exclusion cri-
teria are used to exclude those who have difficulties completing the 
requirements for the study, e.g., language difficulties, use of psycho-
tropic medication, comorbidity more severe than the targeted condi-
tion. Further, client expectations may be higher in specialized uni-
versity research clinics compared to routine clinical care, which may 
further enhance motivation and outcome (Stewart & Chambless, 2009). 
Therapists in university research settings have access to extensive 
training, supervision, and treatment monitoring with an emphasis on 
treatment integrity, more often than their colleagues in routine clinical 
care (Smith et al., 2017). Furthermore, they are more likely to be ex-
perts in the delivery of the particular treatment compared with thera-
pists in community clinics. Also, therapists in university settings typi-
cally have caseloads focused on particular disorders(s), compared with 
the caseloads of therapists in community clinics which typically com-
prise a broad array of disorders and referral problems (Hunsley, 2007;  
Weisz, Ng, et al., 2013; Weisz, Ugueto, et al., 2013). 
Regarding treatment context, there is a discrepancy between uni-
versity research clinics and community clinics. Staff and facilities are 
dedicated to research in the university clinic, and there are resources 
available to do thorough assessment, treatment monitoring, and re-
scheduling of missed appointments or follow-ups which is seldom the 
situation in the community clinics. As such, treatment programs de-
veloped and evaluated under highly controlled conditions in specialized 
research settings may not produce similar results when delivered in 
routine clinical practice (Baker-Ericzen, Hurlburt, Brookman-Frazee, 
Jenkins, & Hough, 2010; Weisz, Jensen-Doss, & Hawley, 2006; Weisz, 
Ng, et al., 2013). Thus, it is important for clinicians to know what may 
be expected from empirically supported treatments of internalizing 
disorders when delivered in routine clinical practice, and how results 
compare with outcomes obtained in specialized university research 
clinics. 
Effectiveness studies are typically seen as the best option for eval-
uating a treatment when delivered in regular clinical practice (Hunsley, 
2007). Efforts to increase external validity most commonly involve 
placing the treatment study within routine clinical care, using regular 
service providers to deliver the treatment, and including patients who 
are ordinary referrals to the clinics (Hunsley & Lee, 2007). Such studies 
can include pretest-posttest designs, quasi-experimental, or experi-
mental designs (Stewart & Chambless, 2009). Importantly, many 
treatment outcome studies are not easily categorized into the two ca-
tegories of efficacy or effectiveness research, but can be placed some-
where along a continuum of internal and external validity (La Greca 
et al., 2009). As such, both efficacy and effectiveness studies are im-
portant to better evaluate and understand the potential effect and im-
pact of a treatment (Hunsley, Elliott, & Therrien, 2014). 
A few reviews and meta-analyses on effectiveness studies in children 
and adolescents have been conducted. The most recent review reporting 
on the effectiveness of empirically supported treatments across various 
control conditions (e.g., active control, waiting list or usual care) with 
children and adolescents, included 20 studies, seven of which on in-
ternalizing disorders (anxiety, n = 2, OCD, n = 2, depression n = 3), 
six of which evaluated CBT (Lee et al., 2013). The review reported 
treatment completion and improvement rates comparable to those re-
ported in benchmark treatment efficacy studies across the range of in-
cluded disorders. Thus, the review provided encouraging preliminary 
evidence of the effectiveness of treatments with established efficacy. 
Other meta-analyses have either focused on studies comparing em-
pirically supported treatments with a specific control condition (i.e., 
usual clinical care, Weisz et al., 2006; Weisz et al., 2013), or examined 
treatment effectiveness across a broad variety of empirically supported 
treatments for a given disorder (Weisz, Kuppens, et al., 2013). Since 
these reviews and meta-analyses, the number of effectiveness studies 
have increased considerably, with a marked increase in studies evalu-
ating CBT across different cultures and countries. An update of this 
literature is therefore warranted. 
The current meta-analysis aims to add information to the existing 
literature by providing a meta-analysis of the effectiveness of CBT for 
internalizing disorders in children and adolescents treated in routine 
clinical care. We selected studies in which patients are referred for 
treatment through usual clinical routes, treatment is delivered by 
clinicians for whom provision of service is a substantial part of the job, 
and treatment is delivered in routine clinical practice. We chose not to 
limit our meta-analysis to RCTs but include open trials to better capture 
all research conducted in routine clinical care contexts and be as 
comprehensive as possible. Background and treatment data, and 
methodological quality may give important information whether there 
are systematic differences between effectiveness and efficacy studies 
that may affect outcome. Thus, systematic evaluations of these char-
acteristics are necessary to inform the field whether differences in effect 
size are attributable to the actual treatment setting and not to other 
variables. Patients applying for treatment at clinics in the community 
are often less interested in whether the treatment is superior to a con-
trol condition, and more interested in the degree of improvement that 
can be expected and the chance of achieving remission following the 
treatment offered. Thus, in this meta-analysis we use the pre-post and 
pre-follow-up effect size, as well as the rate of remission at post-treat-
ment and follow-up assessment as outcome measures. 
Our specific aims were threefold. First, to examine the effectiveness 
of CBT for anxiety disorders, obsessive compulsive disorder, post- 
traumatic stress disorder, and depressive disorders for children and 
adolescents. Second, to evaluate methodological quality in the effec-
tiveness studies, and investigate potential moderators of treatment 
outcome. Third, to examine how the different cognitive behavior 
treatments delivered in routine clinical care fare in comparison with 
efficacy studies for the same disorders, in order to evaluate if CBT in 
effectiveness studies are at the same level as found in efficacy studies. 
2. Method 
The aims and methods of the current meta-analysis have been pre- 
registered in the PROSPERO database with ID CRD42019128709. Two 
independent raters were involved during the steps of the project, except 
for the literature screening of title and abstract conducted by one rater 
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only. The meta-analysis was designed according to the PICOS acronym 
in the following way:  
• Population: children and adolescents with anxiety disorders, OCD, 
PTSD, and depressive disorder  
• Intervention: CBT delivered in routine clinical care  
• Comparison: within-group change. i.e. pre vs. post-data  
• Outcome: primary continuous measure and remission  
• Study design: RCTs and open trials 
The meta-analysis was conducted according to PRISMA (Liberati 
et al., 2009) and AMSTAR 2 (Shea et al., 2017), see online Supplement 
S7 and S8. 
2.1. Literature search 
Studies were identified by a systematic and comprehensive litera-
ture search of electronic databases and scanning reference lists of ar-
ticles. The search was applied to Ovid MEDLINE, Embase OVID, and 
PsycINFO from the start of the data bases to September 28th 2018. An 
updated search was done October 16th 2019. The list of search terms 
utilized to identify potential studies were generated by all three authors 
in collaboration with a university librarian, who conducted the data-
base searches. We used the following search terms to search the data-
bases: Cognitive therapy; behav* therapy; cognitive behav* therapy; 
anxiety (including the different anxiety disorders); depression (in-
cluding the different depressive disorders); Obsessive compulsive dis-
order; OCD; Post traumatic stress disorder; PTSD; Outpatient clinics; 
community mental health services; effectiveness; routine care; regular 
care, community clinic; youth; child*; adolescent and pediatric. For full 
search strategy for Ovid MEDLINE, Embase OVID and PsychINFO, see 
the online Supplement, S1. 
The first author read the titles and abstract of all the papers from 
this initial search to decide whether a study warranted a more detailed 
reading. When there was an indication of a group of patients receiving 
the particular cognitive-behavioral treatment in a non-university set-
ting the full-text was retrieved. The reference lists in the retrieved 
articles were then checked against the database search and any other 
articles that might fulfil the inclusion criteria were retrieved. Although 
research articles were the target of the search, review articles were also 
examined for additional references. Key authors were searched in da-
tabases for additional publications. Unpublished “grey” literature was 
not included in the present study. In total, 338 full-text articles were 
considered for inclusion. The final decision for article inclusion was 
made using a strict set of inclusion and exclusion criteria detailed 
below. The full text articles were read by the first and the third author 
and any disagreements (6% of the articles) were resolved by consensus 
discussion. It was determined that 58 articles were included in the 
present meta-analysis. In addition, we found two studies on specific 
phobia but it was too few to include in the meta-analysis, which was 
done per disorder. 
2.1.1. Inclusion criteria 
In order to be included in the review and meta-analysis a study had 
to:  
1. Be published, or in press, in an English language journal.  
2. Have participants diagnosed with an anxiety or depressive disorder 
or OCD according to DSM or ICD. For PTSD some proportion of 
subclinical cases are accepted since research indicates that they 
often are as severe as those fulfilling full diagnostic criteria 
(Gutermann et al., 2016).  
3. Be testing a form of CBT, cognitive therapy (CT) or behavior therapy 
(BT).  
4. Have participants referred for treatment through usual clinical 
routes.  
5. Be an effectiveness study, i.e. carried out in a non-university setting 
such as clinical routine care or school health care.  
6. Have therapists who are practicing clinicians for whom provision of 
service is a substantial part of the job.  
7. Have a treated sample consisting of at least 10 participants.  
8. Have a maximum participant age of 18.  
9. Provide a measure of the primary disorder treated. 
Fig. 1. Flowchart of the inclusion of studies.  
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2.1.2. Exclusion criteria   
1. The study is a secondary analysis of a previously published study. 
2. The study is an evaluation of a service where the results for in-
dividual disorders cannot be extracted.  
3. The study is not testing a form of CBT, CT, or BT.  
4. The study is testing a combination of CBT and SSRI. 
Fig. 1 shows a flowchart of the inclusion of studies in the present 
meta-analysis. For references to included studies, see online Supple-
ment S2, and for references to studies excluded in the meta-analyses, 
see online Supplement S3. 
2.2. Potential categorical moderators 
In order to include any potential categorical or continuous mod-
erators in the analysis we required that at least 75% of the studies 
provided information on that variable. With lower proportions it is 
questionable if the information extracted is representative of the entire 
body of studies. 
2.2.1. Type of study and conditions 
Type of study was either RCT or open trial. The various conditions 
in the RCTs were classified as CBT (various types of cognitive beha-
vioral treatments exclusively), other forms of psychotherapy, SRI 
(various serotonin reuptake inhibitors), Combo (the combination of 
CBT and SRI), treatment as usual, and waitlist control (WLC). 
2.2.2. Statistical analysis 
Statistical analysis was categorized as intent-to-treat (ITT) if all 
randomized participants were included in the statistical analysis and 
completers (TC) if only the patients that completed the treatment were 
included. 
2.2.3. Format and parental involvement 
Format of therapy was classified as individual, group, family 
treatment, combinations of these, or Internet-based CBT. Degree of 
parental involvement was classified as low if parents were not present 
during sessions but informed about progress of therapy, moderate if 
parents were present during some therapy sessions full-time or only 
part-time of all sessions, and high if parents were present full-time 
during all therapy sessions. 
2.2.4. Therapist profession 
The profession that the majority of the therapists within a study 
belonged to was classified as clinical psychologist, child psychiatrist, 
social worker, nurse, or various professions. 
2.2.5. Continent 
The country in which the study was carried out was categorized as 
North America, South America, Europe, Asia, Australia, or Africa. 
A coding scheme and manual including the variables of interest was 
developed. The data extraction and categorizations were done in-
dependently by the first and the second author and any disagreements 
(7% of the data items) were solved after consensus discussions. 
2.3. Potential continuous moderators 
The following continuous measures on which at least 75% of the 
studies provided information were used as potential moderators: 
number of participants in the study, percent girls, mean age, pre- 
treatment severity (calculated as percentage of the maximum score of 
the rating scale applied), number of therapists in the study, metho-
dology score (see 2.4.), risk-of-bias score (see 2.5.), treatment weeks, 
number of sessions, treatment hours, treatment intensity (hours/week), 
and percent attrition in the study. In addition, we also extracted 
information on percent declining treatment, having a comorbid dis-
order, having a comorbid anxiety disorder, having received treatment 
for the principal disorder previously, currently on drug treatment, and 
duration of the disorder, but these variables did not reach the 75% 
criterion. 
2.4. Methodological quality 
2.4.1. The psychotherapy outcome study methodology rating scale 
(POMRS) 
The scale consists of 22 items covering various important aspects of 
the methodology in psychotherapy outcome research (Öst, 2008). The 
scale consists of the following items: 1. Clarity of sample description, 2. 
Severity/chronicity of the disorder, 3. Representativeness of the 
sample, 4. Reliability of the diagnosis in question, 5. Specificity of 
outcome measures, 6. Reliability and validity of outcome measures, 7. 
Use of blind evaluators, 8. Assessor training, 9. Assignment to treat-
ment, 10. Design, 11. Power analysis, 12. Assessment points, 13. 
Manualized, replicable, specific treatment programs, 14. Number of 
therapists, 15. Therapist training/experience, 16. Checks for treatment 
adherence, 17. Checks for therapist competence, 18. Control of con-
comitant treatments, 19. Handling of attrition, 20. Statistical analyses 
and presentation of results, 21. Clinical significance, 22. Equality of 
therapy hours (for non-WLC designs only). Each item is rated as 
0 = poor, 1 = fair, and 2 = good, and each step has a verbal de-
scription of one or more sentences. The total score can vary from 0 to 44 
points. The internal consistency of the scale was good with a McDo-
nald's ω of 0.81. The first author was trained in the POMRS by the 
developer of the scale. She rated all the studies and inter-rater relia-
bility of the scale (between the first and the third author), based on 20% 
randomly selected and blindly rated studies was ICC(3,1) = 0.94 (95% 
CI 0.81–0.98), which according to Cicchetti (1994) is excellent. 
2.5. Risk-of-bias 
The Cochrane Collaboration tool for assessing risk-of-bias (Higgins, 
Altman, & Sterne, 2011) was used, and the following domains were 
rated: random sequence generation, allocation concealment, blinding of 
outcome assessment, incomplete outcome data, and selective reporting. 
Blinding of patients and therapists cannot be used in psychotherapy 
studies (Borkovec & Sibrava, 2005). A high risk-of-bias in a domain was 
given 1 point, an unclear risk 0.5, and a low risk 0 point. Summarizing 
over the five domains the total score could vary between 0 and 5, with 
higher scores indicating higher risk-of-bias. The first author rated the 
included studies and inter-rater reliability was assessed between the 
first and the third author based on 20% randomly selected and blindly 
rated studies. This yielded an intra-class correlation, ICC(3, 1) = 0.91 
(95% CI 0.71–0.97), which also is excellent. 
2.6. Effect size measures 
We extracted data on both primary and secondary measures in the 
studies. Since some studies used proportion of remitted participants as 
their primary outcome measure, whereas other studies used a con-
tinuous rating scale we decided to include both in this meta-analysis. 
2.6.1. Remission 
Below follows a description of the assessment of remission used in 
the different studies. 
Depression: 6 out of 8 studies (75%) provided data and in 5 it was 
loss of principal diagnosis, whereas 1 used the proportion achieving a 
normal or borderline score on the Clinical Global Impression-Severity 
(CGI) scale. 
Mixed anxiety: 20 out of 22 studies (90.9%) provided data and in all 
but one it was loss of principal diagnosis. The remaining study used a 
combination of CGI-Improvement and Severity scales. 
G.J.H. Wergeland, et al.   Clinical Psychology Review 83 (2021) 101918
4
OCD: 7 out of 10 studies (70%) provided data on remission; 3 used a 
cut-off score (9 or 10 points) on Children's Yale-Brown Obsessive 
Compulsive Scale (CY-BOCS, Scahill et al., 1997), 2 used a ≥ 35% 
reduction on CY-BOCS plus a post-treatment score of ≤12 points, 
whereas 2 used Jacobson and Truax (1991) criteria of a Reliable 
Change Index plus a cut-off score (9 and 12, respectively). 
PTSD: Since we included studies where less than 100% fulfilled 
diagnostic criteria at pre-treatment remission was calculated based on 
the number of participants who fulfilled diagnostic criteria or the cut- 
off criteria for clinical range on the respective scale. Fifteen out of 18 
studies (83.3%) had data on remission; 13 used loss of principal diag-
nosis, whereas 2 used scores in the non-clinical range on the applied 
primary rating scale. Overall 48 out of 58 studies (82.8%) in this meta- 
analysis provided data on remission. 
2.6.2. Continuous rating scales 
When a study named its primary outcome measure among rating 
scales we used that. If none was pinpointed we selected measures in the 
following order if available: independent assessor rating, self-report 
scale (for school-aged children/adolescents), and parent report scale 
(for pre-school children). All studies of depression, OCD, and PTSD 
provided data on a continuous rating scale, whereas in mixed anxiety 
20 of 22 (90.9%) did so. The various rating scales used for the re-
spective studies are described in the online Supplement S4. 
2.6.3. Secondary outcome measures 
Since depression and general anxiety are common comorbid dis-
orders in the anxiety disorders and general anxiety is a common co-
morbidity in depression we extracted data on such variables too. 
However, only 26 of the 50 (52%) anxiety disorder studies had a 
measure of depression and 31 (62%) had a measure of general anxiety. 
Among the 8 depression studies only 2 (25%) had a measure of general 
anxiety. With these low proportions of studies providing the relevant 
data it is questionable if the outcome of a meta-analysis would be re-
presentative so we decided not to carry out one. 
2.7. Meta-analysis 
In order to obtain as large as possible a body of effectiveness studies 
we included both RCTs and open trials in the meta-analysis since 
within-group ES can be calculated from both types of studies. Within- 
group ES was calculated as (Mpre – Mpost)/SDpre according to re-
commendation by Lakens (2013), since there is good reason to assume 
that the interventions influence not only the means but also the stan-
dard deviations. The mean ES was computed by weighting each ES by 
the inverse of its variance. Rate of remission, with event rate as the 
effect measure, was analyzed using mixed effect analysis in the sub-
group analysis. In this analysis a random effects model is used to 
combine studies within each subgroup and a fixed effects model is used 
to compare subgroups and yield the overall effect. When a study pre-
sented intent-to-treat (ITT) data these were used, if not completer data 
were used. 
Before pooling the effect sizes we screened for statistical outliers, 
defined as being above M  ±  2SD. At the post-treatment assessment 
three (4.6%) of the ESs were outliers, and at follow-up assessment there 
were also three (6.4%). For these ESs winsorising (Lipsey & Wilson, 
2001) was used by reducing outliers to the exact value of M + 2SD. The 
software Comprehensive Meta-Analysis (Borenstein, Hedges, Higgins, & 
Rothstein, 2013) was used for all analyses and to correct for small 
sample sizes Hedges's g was calculated. A random effects model was 
used since it cannot be assumed that the ESs come from the same po-
pulation. 
Heterogeneity among ES's was assessed with the Q- and the I-square 
statistic. The possibility of publication bias was analyzed with the trim- 
and-fill method of Duval and Tweedie (2000) as well as Egger's re-
gression intercept (Egger, Davey Smith, Schneider, & Minder, 1998). 
Moderator analyses of continuous variables were carried out with meta- 
regression and for categorical variables with subgroup analysis using 
the mixed effect model. 
2.8. Efficacy studies for comparison 
In order to obtain the efficacy studies to be used in comparison of 
the effect of CBT in effectiveness studies we consulted the most recent 
evidence base update review of psychosocial treatments published in 
the Journal of Clinical Child and Adolescent Psychology for the respective 
disorders included in the present meta-analysis. For depression it was  
Weersing et al. (2017), for mixed anxiety Higa-McMillan et al. (2016), 
for OCD Freeman et al. (2018), and for PTSD Dorsey et al. (2017). In 
some of these reviews the authors referred to earlier reviews, which we 
checked in order to get as comprehensive as possible a list of efficacy 
RCTs. From each of these reviews we listed the RCTs of some kind of 
cognitive behavioral treatment and then deleted those RCTs we had 
already included in the body of effectiveness studies. This resulted in 
the following number of efficacy RCTs for our comparison: depression 
20, mixed anxiety 34, OCD 24, and PTSD 25, for a total of 103 trials. 
These references are listed in the online Supplement S5. 
As for the effectiveness studies we extracted data for the primary 
continuous outcome measure and remission rate, separately at post- 
treatment and follow-up assessment. In order to compare the two ca-
tegories of studies on background variables we also extracted data on 
mean age, proportion of girls, pre-treatment severity (calculated as 
percent of maximum score on the continuous measure), treatment time 
(60 min. hours), and attrition. Other variables, e.g. comorbidity, were 
not reported systematically, or not at all in a large proportion of studies, 
which precluded inclusion as a background variable. 
3. Results 
3.1. Description of the studies 
3.1.1. Background data 
Background data for the included studies are presented Table 1. The 
majority of the 58 studies were done in Europe (n = 29) and North 
America (n = 18), whereas fewer came from Australia (n = 5), Asia 
(n = 4), South America (n = 1), and Africa (n = 1). The total number 
of participants in these studies was 4618 with the following distribu-
tion: OCD 560 in 10 studies, PTSD 1266 in 18 studies, Mixed anxiety 
1790 in 22 studies, and Depression 1002 in 8 studies. There was an 
overall majority of girls (58%), and this was due to the uneven dis-
tribution in Depression (68.8%) and PTSD (64.3%), whereas it was 
almost even in Mixed anxiety (49.9%) and OCD (49.3%). The mean age 
across all studies was 12.5 (SD 2.8) years, but Mixed anxiety had the 
youngest participants (M = 9.9, SD 1.7) and Depression the oldest 
(M = 15.0, SD 1.5). Proportion of participants with comorbidity was 
reported by only 40 studies (69%), and in an unsystematic fashion. 
With that in mind, 51.9% of the participants had at least one comorbid 
disorder, and Mixed anxiety had the highest proportion (62.6%), 
whereas the other disorders varied between 47% and 49%. The mean 
pre-treatment severity across the studies was 56% (SD 15.5). Since 
different measures were used for the various disorders it is not mean-
ingful to compare them on this variable. Only 35 studies (60%) re-
ported what proportion of the participants was on psychotropic medi-
cation at the inclusion to the respective study. The overall mean was 
12.3%, and varied from 3.8% in PTSD and 21.1% in Depression. Fi-
nally, 37 studies (64%) reported what proportion of eligible partici-
pants declined the offer of treatment and the average was 17.4% (range 
14.0–19.1%). 
3.1.2. Treatment data 
Treatment data for the included studies are presented in Table 2. 
The number of therapists per study was on average 13.4 (range 11–18), 
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which indicates the number of participating therapists working at the 
routine clinical sites where the studies were done. Treatments were 
carried out over 11.7 weeks on average (range 9.5 for PTSD to 15.0 for 
Depression) and the mean number of sessions was 11.2. Most studies 
had one session per week. The total hours of treatment was 14.1 (range 
12.9–15.0) and the intensity (hours/week) was on average 2.0. The 
Depression studies had a mean of 1.1, Mixed anxiety 1.2, PTSD 1.5, and 
OCD 4.4. However, the latter mean was completely carried by the two 
Table 1 
Background data of the included studies.              
Disorder and study Country Continent RCT Comparison N % girls Age (M) % Comorbidity % Severity % declining Tx % current drug Tx  
OCD 
Benazon (2002)  US  NA  N   16  50.0  12.5  50.0  56.4   0 
de Haan (1998)  NL  E  Y  SSRI  23  50.0  13.7  18.0  53.8  13.8  0 
Farrell (2010)  AU  A  N   35  45.7  12.3  54.0  58.9  0  17.1 
Reynolds (2013)  GB  E  Y  Other CBT  50  52.0  14.5  66.0  60.2  41.9  18 
Riise (2016)  NO  E  N   27  32.0  13.3  40.9  70.0  21.4  13.6 
Riise (2018)  NO  E  N   41  71.0  15.0  63.0  64.3  32.7  12.2 
Skarphedinsson (2015)  NO, SE, DK  E  Y  SSRI  50  52.0  14.0  46.0  53.3  30.6  0 
Torp (2015)  NO, SE, DK  E  N   269  51.3  12.8  40.5  61.5  0  0 
Valderhaug (2007)  NO  E  N   28  50.0  13.3  62.5  57.8   8.3 
Williams (2010)  GB  E  Y  WLC  21  38.1  13.6  47.6  57.7  0  33.3  
PTSD 
Bicanic (2014)  NL  E  N   55  100.0  16.0    32.1  0 
Catani (2009)  LK  Asia  Y  Other Tx  31  45.2  11.9   55.8  0  
Chemtob (2002)  US  NA  Y  WLC  34  68.8  8.4   53.7  12.8  
Cohen (2011)  US  NA  Y  TAU  124  50.8  9.6   48.7  14.5  
de Roos (2017)  NL  E  Y  Other CBT  103  57.3  13.1  54.4  51.3  21.1  0 
Giannopolou (2006)  GR  E  Y  WLC  20  55.0  9.6   75.9   
Goldbeck (2016)  DE  E  Y  WLC  159  71.7  13.0  34.0  45.7  7.6  15.1 
Habigzang (2016)  BR  SA  N   103  100.0  11.8   33.1   
Jensen (2014)  NO  E  Y  TAU  156  79.5  15.1   47.0  24.5  
Kameoka (2015)  JP  Asia  N   35  74.3  10.9   42.7   
Nixon (2012)  AU  A  Y  Other CBT  34  36.4  10.8   42.4  55.4  
Rossouw (2018)  ZA  Africa  Y  Other PT  63  87.3  15.4  55.6  67.6   
Ruf (2010)  DE  E  Y  WLC  26  46.2  11.5  38.5  63.7   
Salloum (2016)  US  NA  Y  Other CBT  53  49.0  5.0   50.4  29.3  
Scheeringa (2011)  US  NA  Y  WLC  75  33.8  5.3    35.4  
Shein-Szydlo (2016)  MX  NA  Y  WLC  100  64.0  14.9  28.0  64.6  7.4  0 
Van der Oord (2010)  NL  E  N   23  73.9  11.9  69.6  62.5  0  
Webb (2014)  US  NA  N   72  64.0  12.4    8.7   
Mixed anxiety 
Barrett (2015)  AU  A  N   31  38.7  5.7   29.3   
Barrington (2005)  AU  A  Y  TAU  62  64.8  10.0  37.0  55.0   
Bodden (2008)  NL  E  Y  Other CBT  134  59.0  12.4  81.0  84.8  0  2.3 
Crawford (2013)  US  NA  N   17  29.4  10.1  84.2  54.7  0  41.2 
Creswell (2015)  GB  E  Y  Other CBT  211  52.1  10.2  9.5  35.3   25.1 
Creswell (2020)  GB  E  Y  Other PT  136  52.9  9.2   63.8  40.4  0 
Ginsburg (2012  US  NA  Y  TAU  32  62.5  10.3  63.0  66.9  0  
Jolstedt (2018)  SE  E  N   19  63.0  10.5   60.6   
Jonson (2015)  DK  E  N   87  52.9  11.2  77.0  80.0   20.2 
Lau (2010)  HK  Asia  Y  WLC  51  46.7  8.7  23.0  30.1  32.9  
Martinsen (2009)  NO  E  N   21  48.4  9.8  83.0    
Monga (2009)  CA  NA  N   34  59.4  6.5  62.5  41.2   3.1 
Monga (2015)  CA  NA  Y  Other CBT  77  62.3  6.8  85.7  70.1  19.8  0 
Nauta (2001)  NL  E  Y  Other CBT  18  44.4  10.2  78.0  38.9   17 
Nauta (2003)  NL  E  N  Other CBT  79  50.6  11.0  70.0  76.3  11.2  5 
Southam-Gerow (2010)  US  NA  Y  TAU  48  56.2  10.9  72.9  57.2   
Storch (2015)  US  NA  Y  TAU  100  44.0  9.8   55.0  2.9  21 
Tobon (2011)  CA  NA  N   38  38.0  10.3  68.0  70.9   35 
Van Steensel (2015)  NL  E  N   174  40.2  12.4  49.4   13  19 
Wergeland (2014)  NO  E  Y  Other CBT  182  53.0  11.5  77.5  87.1  8.7  6 
Villabö (2018)  NO  E  Y  Other CBT  165  45.5  10.5  67.9  37.9  4.6  0 
Özyurt (2018)  TR  E  Y  WLC  74  34.0  9.7  36.4  40.1  34.5   
Depression 
Charkhandeh (2016)  IR  Asia  Y  Other Tx  188  53.7  14.7   72.2   0 
Goodyear (2017)  GB  E  Y  Other PT  470  74.8  15.6  48.0  70.0   27.2 
Kobak (2015)  US  NA  Y  TAU  76  66.0  15.4     
Melvin (2006)  AU  A  Y  SSRI  73  65.8  15.3  69.0  69.8  9.9  0 
Shirk (2014)  US  NA  Y  TAU  43  83.7  15.5  46.0  47.4  14  39 
Straub (2014)  DE  E  N   15  73.3  16.4  20.0  47.6  21  6.7 
Weersing (2006)  US  NA  N   80  77.0  15.6  53.0  38.1   65 
Weisz (2009)  US  NA  Y  TAU  57  56.0  11.8  60.0  20.1  31.3  9.7 
Note: Country: Codes from the International Organization for Standardization. Codes for the representation of names of countries and their subdivisions. Part 1: 
Country codes. Geneva (Switzerland): The Organization; 1997. (ISO 3166-1: 1997), have been used. RCT = Randomized controlled trial, N = No, Y = Yes, 
SSRI = Selective Serotonin reuptake inhibitors, WLC = Waitlist control, TAU = Treatment as usual. Blanks = Data not provided. % Severity = the mean of the 
sample divided by the maximum severity score of the primary outcome measure.  
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Table 2 
Treatment data of the included studies.                

























Benazon (2002)  CBT + ERP  I  1  Moderate  12  12  12  1.0  0.0  0.0   0 ITT 
de Haan (1998)  ERP + CT  I  8  Low  12  12  12  1.0  4.4  7.7  0.0  0 TC 
Farrell (2010)  CBT+ ERP  I,G  4  Moderate  12  12  16.1  1.3  5.7    0 ITT 
Reynolds (2013)  ERP + CT  I  6  Moderate  14  14  14  1.0  6.4  0.0  12.5  6 ITT 
Riise (2016)  ERP  G  4  High  0.6  4  18  18.0  9.1    0 ITT 
Riise (2018)  ERP  G  9  High  0.6  4  18  18.0  0.0    6 ITT 
Skarphedinsson (2015)  ERP + CT  I  19  Moderate  16  10  15  0.9  16.3  25.0  0.0  6 ITT 
Torp (2015)  ERP + CT  I  44  Moderate  14  14  17.5  1.3  10.4  10.4   36 ITT 
Valderhaug (2007)  ERP + CT  I  8  Moderate  14  12  12  0.9  14.3  14.3   6 TC 
Willians (2010)  CBT  I  3  Low  12  10  10  0.8  9.5  9.1  10.0  3 ITT  
PTSD 
Bicanic (2014)  CBT  G   Moderate  9  9  18  2.0  1.8    12 TC 
Catani (2009)  KIDNET  I  6  Low  2  6  9  4.5  0.0  0.0  0.0  6 ITT 
Chemtob (2002)  EMDR  I  4  Low  3  3  3  1.0  5.9    6 TC 
Cohen (2011)  TF CBT  I  3  Moderate  8  8  6  0.8  29.2  28.3  30.4  0 ITT 
de Roos (2017)  EMDR/CBWT  I  21  Moderate  6  6  4.5  0.8  2.4  2.4  2.3  12 ITT 
Giannopolou (2006)  CBT  G  2  Moderate  7  7  14  2.0  15.0  0.0  30.0  48 TC 
Goldbeck (2016)  TF CBT  I  26  Moderate  16  12  18  1.5  12.2  13.7  10.8  12 ITT 
Habigzang (2016)  CBT  G   Low  16  16  24  1.5  1.0    0 TC 
Jensen (2014)  TF CBT  I  71  Moderate  15  15  15  1.0  15.2  14.9  15.6  18 ITT 
Kameoka (2015)  TF CBT  I  7  Moderate  14  14  21  1.5  8.6    0 ITT 
Nixon (2012)  CBT/CT  I   Moderate  9  9  13.5  1.5  24.1  26.7  21.4  12 ITT 
Rossouw (2018)  PE-A  I   Low  9  9  7  1.0  17.5  19.4  15.6  6 ITT 
Ruf (2010)  KIDNET  I  8  Low  8  8  16  2.0  3.8  7.7  0.0  10 ITT 
Salloum (2016)  TF CBT  I  4  Moderate  12  14  14  1.0  7.5  11.4  0.0  3 ITT 
Scheeringa (2011)  TF CBT  I  4  Moderate  12  12  12  1.0  42.9  34.6  52.2  6 TC 
Shein-Szydlo (2016)  CBT  I  2  Low  12   12  1.0  1.0  2.0  0.0  6 TC 
Van der Oord (2010)  CBWT  I   Low  11  6  5.5  0.5  13.0    12 TC 
Webb (2014)  TF CBT  I  12  Moderate  10  10  10  1.0  12.5    10   
Mixed anxiety 
Barrett (2015)  CBT  G  3  Moderate  10  10  15  1.5  0.0    12 TC 
Barrington (2005)  CBT  I  18  Moderate  12  12  12  1.0  12.9    12 TC 
Bodden (2008)  CBT child  I   Moderate  13  13  19.5  1.5  10.9  3.1  18.8  3 ITT 
Crawford (2013)  Comp. assisted  iCBT  3  Low  12  12  10  0.8  11.8    0 TC 
Creswell (2015)  CBT child  I  10  Moderate  8  8  8  1.0  15.6  21.1  12.6  12 ITT 
Creswell (2020)  CBT parent  P  19  High  8  8  5  0.6  9.7  16.7  3.2  6 ITT 
Ginsburg (2012  CBT  I  11  Moderate  12  8  6  0.8  9.4  5.9  13.3  1 ITT 
Jolstedt (2018)  CBT  iCBT  3  Moderate  12  12  4  0.3  11.0    3 ITT 
Jonson (2015)  CBT  G  16  Moderate  12  10  20  1.7  4.7    3 ITT 
Lau (2010)  CBT  G  6  High  10  9  18  1.8  16.0  4.2  14.3  6 TC 
Martinsen (2009)  CBT  G   Moderate  12  10  15  1.5  14.3    0 TC 
Monga (2009)  CBT  G   High  12  12  12  1.0  5.9  5.9   0 TC 
Monga (2015)  CBT fam  G   High  12  12  12  1.0  0.0  0.0  0.0  12 ITT 
Nauta (2001)  ICBT  I  6  Moderate  12  12  12  1.0  5.6    15 TC 
Nauta (2003)  ICBT  I  27  Moderate  12  12  12  1.0  4.1  10.3  0.0  3 ITT 
Southam-Gerow (2010)  ICBT  I  39  Moderate  22  18  18  1.0  22.9  25.0  20.8  0 ITT 
Storch (2015)  CBT  iCBT  6  Moderate  12  12  12  1.0  8.0  8.1  7.8  1 ITT 
Tobon (2011)  CBT  G  6  Moderate  12  12  18  1.5  10.5    4 TC 
Van Steensel (2015)  CBT  I, F   Moderate  12  12  18  1.5  18.1    24 ITT 
Wergeland (2014)  CBT  I  17  Moderate  10  10  10  1.0  13.4   5.7  47 ITT 
Villabö (2018)  CBT  I  32  Moderate  12  10  15  1.5  12.7  29.1  7.3  24 ITT 
Özyurt (2018)  CBT  G  2  High  8  8  11.5  1.4  12.2  7.1  17.2  4 TC  
Depression 
Charkhandeh (2016)  CBT     12  12  24  2.0  0.0  0.0  0.0  0 TC 
Goodyear (2017)  CBT  I  145  Moderate  20  20  20  1.0  9.6  8.4  10.2  12 ITT 
Kobak (2015)  CBT  iCBT  18  Low  12  12  12  1.0  14.5  10.2  18.9  0 TC 
Melvin (2006)  CBT  I  11  Moderate  12  12  10  0.8  15.6  4.5  19.6  6 ITT 
Shirk (2014)  CBT-m  I  4  Low  12  12  12  1.0  5.7  6.3  5.0  0 ITT 
Straub (2014)  CBT  G  2  Low  5  6  6  1.2  0.0    1 TC 
Weersing (2006)  CBT  I   Low  22  20  20  0.9  0.0    0 ITT 
Weisz (2009)  CBT  I  54  Low  25  16  16  0.6  0.0  0.0  0.0  0 ITT 
Note: F-up = Follow-up, I = Individual therapy, G = Group therapy, iCBT = internet delivered therapy, F = Family therapy, ITT = intention to treat, 
TC = Treatment completers. * = Four studies report on follow-up in separate publications, and data from these publications are included in the follow-up (Tutus 
2017, Jensen 2017, Nixon 2017, Kodal 2018). Blanks = Data not provided.  
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studies by Riise et al. (2016; 2018) with the concentrated exposure and 
response prevention of 18 h over four days. When removing these 
studies from the calculation the intensity for OCD was 1.0. Information 
on continent, therapist and CBT-manual information on the included 
studies are provided in Supplement S9. 
3.2. Methodological data 
3.2.1. Methodology ratings 
The research methodology score had an overall mean of 22.28 (SD 
5.94, 95% CI 20.71–23.84). The studies for the different disorders had 
the following means (SD): Depression 20.50 (5.73), PTSD 21.11 (6.46), 
Mixed anxiety 23.36 (6.11), and OCD 23.40 (4.72). A one-way ANOVA 
yielded a non-significant effect (F(3) = 0.83, p = 0.49). When the 
analysis was restricted to the 38 RCTs the overall mean was 24.42 (SD 
5.61, 95% CI 22.57–26.28). The means for the different disorders were: 
Depression 21.17 (6.43), PTSD 23.54 (5.67), Mixed anxiety 25.80 
(5.23), and OCD 27.00 (4.97), and the ANOVA was non-significant (F 
(3) = 1.39, p = 0.26). 
3.2.2. Risk of bias 
The risk of bias categorization is presented in the online 
Supplement, Table S6. If we delete the 21 open trials from the eva-
luation of the first two domains we find the following proportions of a 
low risk-of-bias: Random sequence 78%, allocation concealment 59%, 
blinding of assessors 47%, incomplete data 64%, and selective reporting 
97%. A high risk-of-bias was found in: Random sequence 0%, allocation 
concealment 3%, blinding of assessors 26%, incomplete data 28%, and 
selective reporting 2%. Thus, it was much more common that these 
studies had a low than a high risk-of-bias regarding the evaluated do-
mains. 
In order to score the risk-of-bias a low risk was given 0, an unclear 
risk 0.5, and a high risk 1 point, which means that the total score could 
vary from 0 to 5 points (see Supplement S6). The total mean score was 
1.60 (SD = 1.27) and the studies within each disorder had the fol-
lowing mean (SD): Depression 1.25 (1.13), PTSD 1.44 (1.44), Mixed 
anxiety 1.71 (1.31), and OCD 1.95 (1.01). A one-way ANOVA yielded a 
non-significant effect (F(3) = 0.58, p = 0.63). Restricting the analysis 
to the RCTs only yielded the following means: Depression 1.25 (1.13), 
PTSD 0.81 (1.15), Mixed anxiety 1.07 (0.96), and OCD 0.92 (1.11), and 
the ANOVA was non-significant (F(3) = 0.15, p = 0.93). 
3.3. Meta-analysis 
3.3.1. Attrition 
Using treatment condition (k = 97) as the unit of analysis the 
overall attrition rate was 12.2% (95% CI 10.1–14.6, z = 18.33, 
p  <  0.001). The different disorders had the following attrition rates: 
Depression 7.1%, Mixed anxiety 12.6%, OCD 13.4%, and PTSD 14.3%, 
with no significant difference between them (Qbetween (3 df) = 4.62, 
p = 0.20). When analyzing dropout rate for the different treatment 
conditions we found the following rates: CBT 11.4%, Other forms of 
psychotherapy 6.6%, SRIs 25.8%, Treatment as usual 14.3%, Waitlist 
control 20.1%, with a significant difference between them (Qbetween (4 
df) = 11.59, p = 0.021). Subsequent pairwise comparisons showed 
that CBT had a lower attrition rate than SRI (Qbetween (1 df) = 7.73, 
p = 0.005) but did not differ significantly from the other conditions. 
3.3.2. Primary continuous measure 
Table 3 displays the mean effect sizes of the primary continuous 
measure for all studies at post-treatment and follow-up assessment, 
which was done on average 10.7 months after the end of therapy. At 
post-treatment the average ES was very large (g = 1.50) and sig-
nificantly different from zero. Heterogeneity was significant and large 
as indicated by the Q- and I2-values. The comparison between disorders 
was also significant and pairwise comparisons showed that OCD had a 
significantly higher ES than PTSD (Qbetween (1 df) = 15.23, 
p  <  0.001), Mixed anxiety (Qbetween (1 df) = 20.33, p  <  0.001), and 
Depression (Qbetween (1 df)  <  13.59, p = 0.001). The other means did 
not differ significantly from each other. 
At follow-up the mean ES (g = 2.13) was significantly higher than 
at post-treatment (Qbetween (1 df) = 14.02, p  <  0.001), but also sig-
nificantly heterogeneous. Once more, the comparison between dis-
orders was significant and pairwise comparisons indicated that OCD 
had a significantly higher ES than PTSD (Qbetween (1 df) = 10.64, 
p  <  0.001), Mixed anxiety (Qbetween (1 df) = 12.54, p  <  0.001), and 
Depression (Qbetween (1 df) = 9.16, p  <  0.001). The differences be-
tween the other means were not significant. 
3.3.2.1. Publication bias. The possibility of publication bias was 
investigated, using Duval and Tweedie's trim-and-fill method and 
Eggers regression intercept. Regarding the post-treatment data the 
trim-and-fill method suggested trimming 25 conditions to the left of 
the mean which would lower the ES from 1.50 to 0.94 (95% CI 
0.74–1.14). The regression intercept had a significant t-value = 4.78, 
p  <  0.001, indicating that publication bias probably is an issue for this 
body of studies. 
3.3.2.2. Moderator analyses. As the mean ES was significantly 
heterogeneous we followed up with moderator analyses. Using 
subgroup analysis Table 4 shows the results for categorical variables 
and there was no significant difference between RCTs and open trials. 
Also, studies with intent-to-treat analysis yielded nominally higher ES 
than studies using completer analysis, which is unexpected. There was 
no significant differences depending on treatment format, degree of 
parental involvement, or therapist profession. However, the continent 
at which the study was carried out was associated with a significant 
difference; studies from Europe had the highest ES. 
Continuous variables on which at least 75% of the studies provided 
information were analyzed with the meta-regression module in the 
CMA program using the fixed effects analysis (see Table 5). The fol-
lowing variables were positive moderators: number of participants in 
the study, mean age of the sample, pre-treatment severity, number of 
therapists in the study, and intensity of the treatment, i.e. higher values 
on these variables were associated with higher ES. However, regarding 
intensity there were two outliers with 18 h of therapy during a single 
week (Riise et al., 2016; Riise, Kvale, Öst, Skjold, & Hansen, 2018); 
when these were removed intensity no longer was a significant positive 
moderator. There were two negative moderators: Proportion of girls in 
the sample and attrition rate, i.e. the higher these proportions the lower 
the ES. This was, however mainly due to PTSD, which had the highest 
proportion of girls and the moderator was no longer significant when 
PTSD-studies were removed. Finally, higher risk-of-bias score was 
Table 3 
Within-group effect size (Hedges' g) for all studies (RCTs and open trials) di-
vided on disorder with treatment condition as unit of analysis.          
Disorder k g 95% CI z-value Q-value p-value I2      
Post-treatment    
All disorders  69  1.50  1.32–1.67  16.86a  753.78  0.001  91.0 
Depression  8  1.28  0.81–1.74  5.40a  21.54*  0.001  
Mixed anxiety  29  1.28  1.03–1.53  9.94a    
OCD  11  2.54  2.05–3.02  10.25a    
PTSD  21  1.43  1.16–1.70  10.28a        
Follow-up    
All disorders  49  2.13  1.85–2.40  14.99a  640.84  0.001  92.5 
Depression  3  1.72  0.95–2.49  4.37a  13.85*  0.003  
Mixed anxiety  23  1.87  1.48–2.26  9.46a    
OCD  7  3.36  2.63–4.10  9.01a    
PTSD  16  2.05  1.75–2.35  13.39a    
Note: k = number of treatment conditions. a p  <  0.0001. * Comparison be-
tween the four disorders.  
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associated with higher ES, whereas the methodology score was not 
significantly associated with ES. 
3.3.3. Remission 
The remission rates at post-treatment and follow-up are presented in  
Table 6. At post-treatment 58.7% of the participants had remitted, 
which was significantly different from 50%, and significantly hetero-
geneous. A subgroup analysis indicated that PTSD had the highest re-
mission rate (77.4%), which was significantly higher that the rates for 
Depression (Qbetween (1 df) = 6.84, p = 0.009), Mixed anxiety (Qbetween 
(1 df) = 36.68, p  <  0.001), and OCD (Qbetween (1 df) = 7.55, 
p  <  0.001). The rates for the other disorders did not differ significantly 
between each other. 
At follow-up assessment the overall remission rate had increased 
significantly (Qbetween (1 df) = 15.59, p  <  0.001), to 71.6%, which 
was significantly different from 50% and heterogeneous. The subgroup 
analysis also showed that the disorders differed significantly between 
each other. Once again, PTSD had the highest remission rate (83.3%), 
which differed significantly from the rates for Depression (Qbetween (1 
df) = 4.93, p = 0.026), Mixed anxiety (Qbetween (1 df) = 7.36, 
p = 0.007), and OCD (Qbetween (1 df) = 4.77, p = 0.029). The differ-
ences between the other rates were not significant. 
3.3.3.1. Publication bias. Eggers regression intercept did not yield a 
significant t-value (1.46, p = 0.15). The trim-and-fill method suggested 
trimming 8 studies, which would have reduced the remission rate from 
58.7% to 54.8% (95% CI 49.5–60.0). Thus, publication bias does not 
seem to be an important problem regarding the remission rate. 
3.3.3.2. Moderator analyses. Table 7 displays the results of the 
subgroup analyses for the categorical variables. The only significant 
variable was parental involvement where treatment conditions with 
low involvement from the parents yielded a higher remission rate than 
conditions with moderate or high parental involvement. As for the 
primary continuous measure open trials did not have a significantly 
higher remission rate than RCTs and treatment completer analyses did 
not differ from intent-to-treat analyses. 
The results of the meta-regression analysis of continuous variables 
are shown in Table 8. The following variables were significant positive 
moderators: percent girls in the sample (which disappeared when the 
PTSD-studies were removed), mean age, total hours of therapy, and 
treatment intensity, i.e. higher values on these variables were asso-
ciated with higher remission rates. As was the case for the g-value 
(Table 5), the significant effect for intensity was driven by two outliers 
and when those studies were removed it was no longer significant. 
Number of therapists in the study was also a positive moderator but it 
was due to an outlier with an extremely high number of therapists 
(n = 145), and removing this study yielded a non-significant effect. 
Only two variables, methodology score and pre-treatment severity, 
were negative moderators; i.e. more stringent methodology and higher 
pre-treatment severity were associated with lower remission rate. 
3.4. Efficacy-effectiveness comparison 
3.4.1. Background and treatment variables 
Table 9 presents a comparison between efficacy and effectiveness 
studies on some background and treatment variables. There were no 
significant differences between the two types of studies on mean age at 
the start of treatment, proportion of girls in the studies, or the pre- 
treatment severity (as assessed by the primary continuous outcome 
measure). Regarding treatment time (hours of therapy) the effective-
ness studies had nominally lower means than efficacy studies for all 
four disorders, and the difference was significant for mixed anxiety 
disorders. Finally, the attrition rate was lower for effectiveness than 
efficacy studies in depression, but did not differ significantly for the 
other disorders. 
Table 4 
Subgroup analysis of the overall effect size for all studies at post-treatment.        
Variable k g 95% CI Qb-value p-value  
Type of study     2.60  0.10 
RCT  49  1.42  1.23–1.62   
Open trial  20  1.80  1.42–2.18   
Statistical analysis     2.24  0.13 
Intent-to-treat  47  1.58  1.36–1.80   
Treatment completers  22  1.31  1.04–1.58   
Format     2.97  0.23 
Individual  47  1.40  1.20–1.60   
Group  14  1.72  1.20–2.24   
Internet CBT  4  1.75  1.32–2.18   
Parental involvement     2.45  0.29 
Low  15  1.57  1.14–2.01   
Moderate  45  1.41  1.21–1.61   
High  8  2.01  1.24–2.79   
Therapist profession     5.68  0.13 
Clinical psychologist  43  1.54  1.32–1.75   
Child psychiatrist  2  1.93  1.41–2.45   
Social worker  7  1.00  0.42–1.58   
Various professions  11  1.41  0.97–1.85   
Continent     11.22  0.011 
Europe  37  1.75  1.51–2.00   
North America  20  1.14  0.85–1.42   
Australia  6  1.26  0.81–1.70   
Asia  4  1.35  0.91–1.78   
Note: k = number of treatment conditions, Qb = Q between subgroups.  
Table 5 
Meta-regression analysis of the overall effect size for all studies at post-treat-
ment.       
Variable k Point est. z-value p-value  
Number of participants  69  0.002  4.99  0.0001 
Percent girls  69  −0.004  −2.48  0.013 
PTSD removed  48  0.004  1.49  0.135 
Mean age  69  0.086  8.35  0.0001 
Pre-treatment severity  63  1.828  11.96  0.0001 
Number of therapists  55  0.006  5.08  0.0001 
1 outlier removed  54  0.004  2.02  0.042 
Methodology score  69  0.004  1.24  0.216 
Risk-of-bias  69  0.094  5.16  0.0001 
Weeks of treatment  69  −0.013  −1.88  0.059 
Number of sessions  69  −0.002  −0.21  0.837 
Total hours of treatment  69  −0.004  −0.92  0.356 
Intensity  69  0.169  7.10  0.0001 
2 outliers removed  67  −0.052  −0.80  0.426 
Attrition  69  −0.017  −5.07  0.0001 
Note: k = number of treatment conditions.  
Table 6 
Rates of remission for all studies divided on disorder.          
Disorder k % 95% CI z-value† Q-value p-value I2  
Post-treatment        
All disorders  54  58.6  53.6–63.4  3.34a  244.87  0.001  78.4 
Depression  5  53.2  34.6–70.9  0.32  37.33*  0.001  
Mixed anxiety  27  50.7  45.3–56.2  0.27    
OCD  7  56.7  41.7–70.6  0.87    
PTSD  15  77.4  71.3–82.6  7.50b    
Follow-up        
All disorders  39  71.6  67.3–75.5  8.96b  109.94  0.001  65.4 
Depression  3  53.5  25.9–79.1  0.23  9.20*  0.027  
Mixed anxiety  22  69.4  64.1–74.3  6.65b    
OCD  3  72.6  67.6–77.1  7.92b    
PTSD  11  83.3  74.9–89.3  6.11b    
Note: k = number of treatment conditions. a p  <  0.001, b p  <  0.0001. † Test 
if significantly different from 50%, * Comparison between the four disorders.  
G.J.H. Wergeland, et al.   Clinical Psychology Review 83 (2021) 101918
9
3.4.2. Effect size on primary outcome measure 
Table 10 presents the subgroup analyses comparing the un-
controlled effect size (Hedges' g) for efficacy and effectiveness studies 
within each disorder. At post-treatment assessment (upper part of  
Table 10) there were no significant differences between the two types of 
studies. However, at follow-up assessment effectiveness studies yielded 
a significantly higher ES than efficacy studies for PTSD, whereas the 
differences for the remaining disorders were non-significant. 
3.4.3. Remission 
Table 11 contains subgroup analyses comparing the remission rates 
at post-treatment and follow-up assessment. The efficacy vs. effective-
ness comparison regarding follow-up period was not significant for any 
disorder, and varied from 6.3 (SD 5.5) months for effectiveness studies 
in depression to 17.9 (SD 19.9) months for efficacy studies in mixed 
anxiety. The post-treatment remission rates (upper part of Table 11) did 
not differ between study types for three of the disorders, but in mixed 
anxiety disorders the efficacy studies had a significantly higher rate 
than the effectiveness studies. However, at follow-up assessment (lower 
part of Table 11) the difference within mixed anxiety disorders was no 
longer significant. The increase in remission rate from post-treatment 
was 18.7 percentage points for effectiveness studies and 9.7 for efficacy 
studies. The difference in remission rates was not significant for the 
other disorders. 
3.4.4. Comparison of RCTs only 
Since the outcome presented in Tables 10 and 11 might have been 
unduly influenced by open trials we repeated the analyses using only 
RCT effectiveness studies. Table 12 summarizes the results across dis-
orders and there were no significant differences between efficacy and 
effectiveness studies on remission rates or effect size at post-treatment 
or follow-up assessment. 
4. Discussion 
The overall focus of this meta-analysis was to examine whether 
cognitive behavior therapy for anxiety disorders, obsessive-compulsive 
disorder, post-traumatic stress disorder, and depressive disorder in 
children and adolescents works in routine clinical care. Our main 
finding supports the effectiveness of CBT in reducing internalizing 
disorders and symptoms, and the outcomes are comparable with how 
CBT works in university settings, i.e. efficacy studies. Our results pro-
vide updated evidence about the degree of improvement which can be 
expected following the treatment offered in routine clinical care when 
carried out by therapists having appropriate training. 
Across the different disorders, the pre-post treatment effect size for 
disorder-specific outcome measures was very large and over half of the 
youth who started treatment achieved remission at the end of treat-
ment. Our results also showed that some disorders yielded more fa-
vorable outcomes, with OCD having the highest effect size, and PTSD 
the highest remission rate. Furthermore, the treatment effects sig-
nificantly increased at follow-up on average 10.7 months after the end 
of therapy. Almost two thirds of youth achieved remission at follow-up, 
indicating that they continued to improve after therapy had ended. 
Several explanations for this continued improvement may apply. First, 
the improvements may relate to a delayed treatment effect, which may 
stem from a prolonged consolidation of acquired skills among youth 
and their parents (Ishikawa, Okajima, Matsuoka, & Sakano, 2007). 
Also, the time available to conduct exposure exercises in CBT is limited 
in most manual-based treatment programs, which were carried over 
11.7 weeks on average in the current meta-analysis. However, the mean 
follow-up period was 10.7 months which meant that the youth had 
much more time to apply the acquired skills after ending treatment, 
leading to improved outcome at follow-up. Also, a possible explanation 
could be maturation and spontaneous recovery among children and 
adolescents with anxiety disorders (Adler Nevo et al., 2014). Similar 
findings of continued improvement are found in effectiveness studies 
(Kodal et al., 2018) and efficacy studies (Gibby, Casline, & Ginsburg, 
2017) for mixed anxiety disorders in children and adolescents. 
Moreover, the overall attrition rate across the disorders was only 
12.2%. This figure is lower than the 20% in the review by Lee et al. 
(2013). Importantly, there was no significant difference in the attrition 
rates between the different disorders, indicating that these treatments 
were acceptable to youth and their caregivers. Taken together, these 
findings suggest that youth receiving CBT for internalizing disorders in 
routine clinical care improved significantly and substantially following 
treatment, and that CBT is effective in clinical settings. We attempted to 
broaden the view by extracting effect data for the common comorbid 
disorders (depression for anxiety disorders and anxiety for depressive 
disorders) and quality of life. However, only 48% of the studies pro-
vided data on comorbid disorders and much fewer on quality of life and 
if we were to meta-analyze them the results would most probably not be 
representative for the entire body of studies. 
Our findings expand the results from a previous review of the ef-
fectiveness of CBT for internalizing and externalizing disorders in youth 
(Lee et al., 2013). Considerable evidence regarding the topic has been 
Table 7 
Subgroup analysis of the remission rate for all studies at post-treatment.        
Variable k % 95% CI Qb-value p-value  
Type of study     1.09  0.30 
RCT  40  56.8  51.1–62.3   
Open trial  14  63.1  52.4–72.6   
Statistical analysis     1.33  0.25 
Intent-to-treat  41  56.7  51.5–61.6   
Treatment completers  13  64.7  51.7–75.9   
Format     0.05  0.98 
Individual  37  57.7  51.8–63.3   
Group  10  59.7  42.9–74.5   
Internet CBT  4  58.1  44.6–70.5   
Parental involvement     6.11  0.047 
Low  7  72.5  60.4–82.0   
Moderate  38  55.5  49.8–61.1   
High  6  58.8  38.2–76.7   
Therapist profession     4.03  0.13 
Clinical psychologist  33  61.2  54.9–67.1   
Social worker  7  64.7  49.4–77.5   
Various professions  11  49.5  38.8–60.2   
Continent     2.08  0.56 
Europe  29  56.6  50.8–62.1   
North America  16  57.7  45.4–69.0   
Australia  5  55.5  34.8–74.4   
Asia  2  69.2  52.4–82.1   
Note: k = number of treatment conditions, Qb = Q between subgroups.  
Table 8 
Meta-regression analysis of the overall remission rate for all studies at post- 
treatment.       
Variable k Point est. z-value p-value  
Number of participants  53  −0.0001  −1.10  0.27 
Percent girls  53  0.017  4.76  0.0001 
PTSD removed  39  0.001  0.13  0.90 
Mean age  53  0.056  2.43  0.015 
Pre-treatment severity  48  −1.453  −5.66  0.0001 
Number of therapists  42  0.003  2.04  0.041 
1 outlier removed  41  −0.0006  −0.18  0.86 
Methodology score  53  −0.036  −4.98  0.0001 
Risk-of-bias  53  0.011  0.33  0.74 
Weeks of treatment  53  −0.007  −0.57  0.57 
Number of sessions  53  0.007  0.50  0.61 
Total hours of treatment  53  0.019  2.01  0.04 
Intensity  53  0.062  3.45  0.0006 
2 outliers removed  51  0.183  1.62  0.11 
Attrition  53  −0.006  −0.92  0.36 
Note: k = number of treatment conditions.  
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generated since the Lee et al. review was published in 2013. Using si-
milar inclusion criteria but including also PTSD, the number of effec-
tiveness studies for internalizing disorders has almost increased ten- 
fold, with a total of 58 studies included in this meta-analysis. This in-
crease reflects the effort to adopt evidence-based interventions and to 
evaluate their effectiveness. Consistent with findings from Lee et al. 
Table 9 
Some background and treatment data (M and SD) for efficacy and effectiveness studies in the different disorders.         
Disorder k Age (years) % Girls Severity % Attrition Tx time  
Depression   p = 0.35  p = 0.10  p = 0.08  p = 0.001  p = 0.30 
Efficacy  24  14.0 (2.8)  57.2 (15.7)  36.6 (10.9)  15.4 (13.3)  19.7 (9.9) 
Effectiveness  8  15.0 (1.4)  67.6 (11.2)  52.2 (19.6)  5.1 (3.8)  15.4 (6.4) 
Mixed anxiety   p = 0.87  p = 0.72  p = 0.95  p = 0.97  p = 0.01 
Efficacy  59  9.9 (1.8)  48.7 (12.9)  58.0 (18.5)  10.0 (8.6)  15.1 (5.3) 
Effectiveness  29  9.9 (1.7)  49.9 (10.0)  57.8 (19.5)  10.1 (9.5)  12.0 (4.1) 
OCD   p = 0.12  p = 0.40  p = 0.21  p = 0.39  p = 0.37 
Efficacy  27  12.0 (2.5)  46.1 (9.6)  62.0 (6.1)  6.1 (7.5)  15.4 (4.6) 
Effectiveness  11  13.3 (1.3)  49.2 (10.2)  59.4 (4.8)  8.5 (7.4)  14.0 (2.8) 
PTSD   p = 0.64  p = 0.46  p = 0.57  p = 0.81  p = 0.24 
Efficacy  33  10.8 (2.7)  68.3 (19.8)  56.0 (16.1)  14.9 (10.5)  14.8 (7.1) 
Effectiveness  21  11.2 (3.2)  63.8 (19.9)  52.7 (10.8)  15.5 (14.4)  12.5 (5.8) 
Note: k = number of treatment conditions, Severity = percentage of the maximum score on the primary outcome measure. Tx time = number of 60 min therapy 
hours.  
Table 10 
Effect sizes (Hedges' g) for efficacy and effectiveness studies within the different disorders.          
Disorder Study type k g 95% CI z-value Qbetween† p-value  
Post-treatment 
Depression Efficacy  19  1.31  1.01–1.62  8.46a  0.06  0.81  
Effectiveness  7  1.24  0.71–1.77  4.62a   
Mixed anxiety Efficacy  60  1.32  1.13–1.52  13.12a  0.002  0.97  
Effectiveness  28  1.32  1.04–1.59  9.45a   
OCD Efficacy  33  2.50  2.25–2.76  19.31a  0.86  0.35  
Effectiveness  11  2.29  1.92–2.66  12.05a   
PTSD Efficacy  31  1.18  0.96–1.41  10.28a  1.92  0.17  
Effectiveness  20  1.44  1.15–1.73  9.81a    
Follow-up 
Depression Efficacy  12  1.54  1.18–1.90  8.41a  0.11  0.74  
Effectiveness  3  1.69  0.90–2.49  4.17a   
Mixed anxiety Efficacy  47  1.84  1.57–2.11  13.39a  0.06  0.81  
Effectiveness  22  1.91  1.47–2.34  8.63a   
OCD Efficacy  20  2.70  2.31–3.08  13.67a  3.06  0.08  
Effectiveness  7  3.51  2.69–4.33  8.35a   
PTSD Efficacy  26  1.42  1.16–1.69  10.44a  8.45  0.004  
Effectiveness  16  2.02  1.72–2.32  13.17a   
Note: k = number of comparisons. a p  <  0.0001. † Comparison Efficacy vs. Effectiveness within the respective disorders.  
Table 11 
Remission rates for efficacy and effectiveness studies for the different disorders.          
Disorder Study type k % 95% CI z-value* Qbetween† p-value  
Post-treatment 
Depression Efficacy  20  55.5  47.3–63.4  1.31  0.15  0.70  
Effectiveness  6  51.7  35.1–68.0  0.85   
Mixed anxiety Efficacy  51  60.3  56.0–64.4  4.64c  7.57  0.006  
Effectiveness  27  50.6  45.2–56.0  0.21   
OCD Efficacy  26  50.7  43.9–57.5  0.21  0.50  0.48  
Effectiveness  7  56.7  41.7–70.6  0.87   
PTSD Efficacy  13  72.1  64.6–78.6  5.33c  1.36  0.24  
Effectiveness  15  77.4  71.3–82.6  7.50c    
Follow-up 
Depression Efficacy  8  66.7  58.3–74.2  3.77c  0.77  0.38  
Effectiveness  3  53.5  25.9–79.1  0.82   
Mixed anxiety Efficacy  45  70.0  64.8–74.8  6.91c  0.04  0.83  
Effectiveness  22  69.3  63.8–74.2  6.52c   
OCD Efficacy  12  65.5  53.6–75.7  2.54a  1.41  0.24  
Effectiveness  3  72.6  67.6–77.1  7.92c   
PTSD Efficacy  4  78.7  61.3–89.6  3.02b  0.42  0.52  
Effectiveness  13  83.5  75.9–87.6  6.94c   
Note: k = number of comparisons. a p  <  0.05, b p  <  0.01, c p  <  0.0001. ⁎ Test if significantly different from 50%. † Comparison Efficacy vs. Effectiveness within 
the respective disorders.  
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(2013), the majority of the included studies were conducted outside of 
North America. However, several more studies from different countries 
were included in the current meta-analysis, indicating an increased 
effort to address the transportability and generalizability of interven-
tions developed in North America to other countries and cultures (see 
Supplement S9). 
The meta-analysis revealed a significant heterogeneity among the 
effect sizes and remission rates in the analysis with all comparisons. 
Thus, we examined some characteristics of the patient sample and 
treatment variables as potential moderators influencing treatment 
outcome. When analyzing all the studies together, older age was asso-
ciated with better outcome. This finding may be difficult to interpret, as 
age has been found to moderate treatment outcome differently across 
the disorders. For example, older age was positively associated with 
outcome for depressive disorders (Weersing et al., 2017), negatively 
associated with outcome in OCD (Freeman et al., 2018), whereas mixed 
finding for age and outcome was found for anxiety disorders (Higa- 
McMillan et al., 2016; Öst & Ollendick, 2017). Finally, for PTSD, age 
was found to be unrelated to treatment (Dorsey et al., 2017). Thus, the 
variability across the disorders challenges the interpretation of the re-
sults. 
Further, we found that pre-treatment severity moderated the effect 
size positively and remission rate negatively. This finding is probably 
due to the greater room for improvement for those with higher pre- 
treatment symptom levels, resulting in a higher within-group effect 
size. On the other hand, a higher pre-treatment severity makes remis-
sion harder to achieve, and as such these patients end treatment with a 
higher symptom level. Such findings are in line with those reported in 
treatment outcome studies for mixed anxiety (Knight, McLellan, Jones, 
& Hudson, 2014; Lundkvist-Houndoumadi, Thastum, & Hougaard, 
2015), OCD (Freeman et al., 2018), and depressive disorders (Weersing 
et al., 2017). 
The significant association between number of therapists and re-
mission was probably due to one study with a high number of thera-
pists; when excluding this study number of therapists no longer mod-
erated remission. Similarly, the association between intensity of 
treatment and outcome was no longer significant when excluding two 
studies for OCD with exposure and response prevention of 18 h over 
four days. When removing these two studies, treatment intensity no 
longer moderated outcome. Number of participants in the study was 
also associated with higher effect size, but not remission rate. This is 
encouraging since small studies do not seem to be driving the high ES 
for these effectiveness studies. Also, a higher attrition rate was asso-
ciated with lower effect size, but was unrelated to remission. The lower 
effect size could be explained by attrition causing a more conservative 
and less precise estimate of change in the intention-to-treat analyses. 
Furthermore, we found a significant association between continent and 
effect size. A possible explanation to this finding is that the organization 
of routine clinical care might be different in different continents, 
whereas the organization of care in the more privileged university 
settings might be more uniform over continents. 
We found that gender moderated outcome both negatively and 
positively, i.e. a higher proportion of girls in the sample was associated 
with both a lower effect size and a higher remission rate. Across the 
disorders, gender is most often not found to significantly moderate 
treatment outcome (Dorsey et al., 2017; Freeman et al., 2018; James, 
James, Cowdrey, Soler, & Choke, 2015; Weersing et al., 2017). Separate 
analyses showed that the association between gender and outcome was, 
however, completely due to the PTSD studies; when excluding these 
studies gender no longer moderated outcome. 
The finding that the degree of parental involvement in treatment 
was inversely related to outcome is somewhat unexpected. Our result 
may be related to the treatment of PTSD, with the high remission rate 
found for this disorder, and in which low parental involvement was 
common in several of the studies. Similar findings of low parental in-
volvement being positively related to outcome have been reported in a 
recent meta-analytic review of brief, intensive and concentrated CBT 
treatments for anxiety in children (Öst & Ollendick, 2017). One possible 
hypothesis could be that in treatments with low parental involvement 
the child may feel more free to test various anxiety-arousing behaviors 
under the guidance of the therapist. On the other hand, a high parental 
involvement may mean a continuation of old interaction patterns be-
tween parent and child, making it more difficult for the child to try new 
behaviors that will be helpful in reducing anxiety. Mixed results re-
garding the role of parental involvement in CBT have been found in 
previous meta-analyses (Dorsey et al., 2017; Thulin, Svirsky, Serlachius, 
Andersson, & Öst, 2014; Weersing et al., 2017). 
Regarding methodological aspects, it is encouraging that the effect 
size and remission rates were not moderated by type of studies, sta-
tistical analysis, or by the treatment variables such as format, therapist 
profession, number of sessions, or weeks of treatments. These results 
provide confidence in the overall findings of the meta-analysis. 
We found that higher risk-of-bias score was associated with higher 
ES, but not with remission. Although methodological flaws were noted 
in some of the studies, the total mean score was 1.6 (SD = 1.27) with a 
non-significant difference between the disorders. When excluding the 
uncontrolled trials, our overall results showed that it was more common 
with a low than a high risk-of-bias. It may be that the more recent RCTs 
carried out in routine clinical care apply the CONSORT statement 
(Altman, Moher, & Schulz, 2012) to a larger extent, and thus more 
information on the methods to evaluate risk-of-bias is provided. 
All studies were evaluated on methodological aspects by using the 
psychotherapy outcome study methodology rating scale developed by  
Öst (2008). The results showed an overall mean of 22.28 for the dif-
ferent disorders. This result is comparable to a recent meta-analyses of 
brief, intensive and concentrated CBT treatment for anxiety in children 
(Öst & Ollendick, 2017), but somewhat lower than in a previous meta- 
analyses on OCD in children (Öst, Riise, Wergeland, Hansen, & Kvale, 
2016). Comparisons between the different disorders yielded a non- 
significant difference, indicating an overall fair methodological quality 
of the included studies. However, regarding moderator analyses, a 
higher methodological score was associated with lower remission rates, 
but did not moderate effect size of continuous outcomes. This dis-
crepancy makes it difficult to draw firm conclusions about the sig-
nificance of methodological quality for the outcome of the included 
effectiveness studies. 
We conducted a publication bias analysis and identified publication 
bias as a potential problem when using effect size as outcome measure 
for the included studies. For the overall effect size the trim-and-fill 
method indicated that 25 studies should be trimmed, which would have 
reduced the mean effect size from 1.50 to 0.94, a reduction of 37.3%. 
No publication bias was evident when using remission as outcome. 
Table 12 
Effect sizes for randomized controlled studies only: all disorders combined.         
Study type k ES 95% CI z-value Qbetween† p-value  
g-value at post-treatment 
Efficacy  143  1.55  1.41–1.68  22.45b  2.49  0.12 
Effectiveness  47  1.36  1.17–1.55  13.85b   
g-value at follow-up       
Efficacy  105  1.83  1.67–2.00  21.23b  0.06  0.80 
Effectiveness  37  1.87  1.58–2.16  12.76b    
Remission rate at post-treatment 
Efficacy  110  58.6  55.3–61.8  5.12b  0.01  0.95 
Effectiveness  41  58.8  52.7–64.6  2.83a   
Remission rate at follow-up       
Efficacy  69  69.3  65.2–73.1  8.58b  1.31  0.25 
Effectiveness  33  73.0  67.8–77.7  7.78b   
Note: k = number of comparisons. a p  <  0.01, b p  <  0.0001. † Comparison 
Efficacy vs. Effectiveness.  
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Using the trim-and-fill method and Egger's test, the effects of publica-
tion bias cannot be ruled out in evaluation the overall impact of ef-
fectiveness studies. 
We compared our outcomes to efficacy studies to evaluate whether 
the magnitude of improvement achieved in routine clinical care is at the 
same level as randomized controlled trials from specialized research 
settings. With very few exceptions, this was the case. The effectiveness 
studies of mixed anxiety, OCD, PTSD, and depression generated post- 
treatment effect sizes very close to the effect sizes from efficacy studies 
(p-values 0.17–0.97), and the effect sizes achieved in both settings were 
in the very large range (1.18 to 2.50 at post- and 1.42 to 3.51 at follow- 
up assessment). Only for PTSD, there was a difference in the effect size 
at follow-up in favor of studies conducted in routine clinical care. Such 
a difference favoring PTSD was also found in a meta-analysis of effec-
tiveness studies of CBT for adult anxiety disorders (Stewart & 
Chambless, 2009). Furthermore, remission rates for OCD, PTSD, and 
depression were comparable to the efficacy studies. Only in the case of 
mixed anxiety, the remission rate was lower in effectiveness studies at 
post-treatment, but not at follow-up. This finding for mixed anxiety at 
post-treatment may be explained by the difference in number of treat-
ment sessions applied (12.0 for effectiveness and 15.1 for efficacy stu-
dies), as this has been related to outcome (Ishikawa et al., 2007). Im-
portantly, there were no differences between the effectiveness and 
efficacy studies on effect sizes or remission rates when we excluded the 
uncontrolled effectiveness studies and only analyzed RCTs, providing 
confidence in the findings. Regarding attrition rates, our results corre-
sponds to the attrition rates of 4.2% found in efficacy studies for de-
pression (Yang et al., 2017), the 10.8% for mixed anxiety (James et al., 
2015), the 12.7% for OCD (Öst et al., 2016), and the 14.4% for PTSD 
(Gutermann et al., 2016). The only difference in the background and 
treatment variables was fewer treatment sessions for mixed anxiety and 
lower attrition rate for depression in the effectiveness studies. There 
were no differences in mean age, proportion of females or pre-treatment 
severity between the effectiveness and efficacy studies for any of the 
disorders, indicating more similarities than differences between the 
samples on these variables. Overall, the results provide positive evi-
dence for the generalizability of treatments developed in university 
research settings to routine clinical care. Moreover, our results are 
consistent with those of previous reviews finding that results of CBT for 
internalizing disorders from university research settings can be gen-
eralized to routine clinical care in youth (Lee et al., 2013), and adults 
(Hans & Hiller, 2013a, 2013b; Stewart & Chambless, 2009). Although 
CBT in general had positive effects on outcomes, there is still a large 
proportion of children and adolescents who do not recover after CBT. 
This finding is in line with recent meta-analyses of the effect of em-
pirically supported youth psychotherapies across a broad variety of 
disorders, and indicates a need for improved therapies (Weisz et al., 
2017; Weisz et al., 2019). 
Some limitations warrant consideration. We only included peer-re-
viewed published or in press studies in English language journals. 
Studies published in other languages could have provided us with ad-
ditional information about the effectiveness of CBT for internalizing 
disorders. Furthermore, the inclusion of only published studies could be 
viewed as a limitation. However, our pool of studies spanned three 
decades. Including unpublished studies could have introduced bias as it 
could have been easier to identify unpublished studies from more re-
cent compared to earlier decades. Also, titles and abstracts were 
screened by one rater only. According to the PRISMA guideline the use 
of two independent raters when screening title and abstract may reduce 
the possibility of rejecting relevant reports. However, by reading 338 
full-text articles and including 17.2% of them in the current meta- 
analyses the risk of missing many relevant studies that would have 
changed the results is probably low. Another limitation may be our 
classification of effectiveness studies. Although classification criteria 
were predefined and assessment could be made reliably by trained 
raters, studies differed on the quality of reporting the needed 
information. Thus, judgment was based on the limited and sometimes 
ambiguous information available, and perhaps some studies are missed 
that should have been included. There are examples in the literature 
where authors classify a study as effectiveness when it is classified by us 
as not (Ale, McCarthy, Rothschild, & Whiteside, 2015; Lee et al., 2013). 
Furthermore, we cannot rule out that there may be other differences 
in the background and treatment variables between the effectiveness 
and efficacy studies that moderates treatment outcome, since we used 
the criterion that at least 75% of the effectiveness studies in our meta- 
analysis had to provide information on a variable to be included in the 
moderator analyses. The use of pre-post standardized mean difference 
to indicate treatment effects in meta-analyses has been problematized 
in a recent study, as it can contribute to biased outcomes and does not 
provide reliable information about the effects of the intervention 
(Cuijpers, Weitz, Cristea, & Twisk, 2017). However, for evaluation of 
improvement found in routine clinical care compared with improve-
ment found in efficacy studies these analyses are still considered in-
formative (Cuijpers et al., 2017; van der Lem, van der Wee, van Veen, & 
Zitman, 2012). It should also be noted that there were no third-wave 
CBT studies among the studies included in the meta-analysis, and the 
findings may therefore not apply to these forms of therapy. Finally, it 
may be claimed that the effectiveness of a CBT program is demonstrated 
when it exceeds the effects of the treatment youth and families usually 
received in the clinic, i.e. usual clinical care (Weisz, Kuppens, et al., 
2013; Weisz, Ugueto, et al., 2013). However, our aim was to examine 
the degree of improvement that can be expected and the chance of 
achieving remission following CBT for internalizing disorders when 
provided by trained therapist in routine clinical care. Thus, a compar-
ison with usual care was outside the scope of the current meta-analysis. 
Future meta-analyses regarding CBT might want to include studies 
with single-case designs once consensus on how to calculate effect size 
has been reached and if such effect sizes can be combined with those 
from RCTs for an overall effect size. Furthermore, when rating the 
studies' methodological quality there was a lack of consistency in the 
reporting of the included studies. Although we selected studies that met 
our inclusion criteria, there was variability in the background and 
treatment data provided, e.g. reporting of attrition, intent to treat or 
completer analyses, and information of sample characteristics such as 
comorbidity and use of psychopharmacological treatments. Use of the 
POMRS, or a similar scale, is recommended in future meta-analyses. In 
addition, evaluation of treatment integrity and researcher allegiance 
effects might be valuable. 
Our findings demonstrate overall encouraging treatment outcomes 
for internalizing disorders, and suggest that clinicians can be confident 
about the effectiveness of CBT treatments in routine clinical care. 
Adequately trained clinicians that provide these treatments in their 
work with youth in routine clinical care can achieve outcomes com-
parable to those in university research clinic settings both at post- 
treatment and at follow-up. At the same time, the results also suggest 
there is room for improvement. A substantial number of clients do not 
respond to the treatments currently available. Although treatment ef-
fects are not lost when programs are transported from research clinics 
to routine clinical care, there is a need to further develop and imple-
ment effective interventions for children and adolescents with inter-
nalizing disorders to improve outcome. 
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